Ebola Outbreak Surpasses 3,000 Cases as First Human Vaccine Trial for Rare Bundibugyo Virus Begins

discovermagazine - Learn how a rare Ebola strain has fueled one of the largest outbreaks on record and what the first human vaccine trial could mean for containing the outbreak.

AI Summary: An Ebola outbreak in eastern DR Congo has surpassed 3,000 reported cases and is poised to become the second-largest on record. Authorities have launched the first human vaccine trial targeting the Bundibugyo strain while laboratory tests show stockpiled Ebola vaccines generate antibodies against Bundibugyo, intensifying both response operations and urgent vaccine research.


Race for a Bundibugyo vaccine: trials and lab progress


Strained response: strikes, unpaid staff, funding and leadership shake-up

5 wks / abcnews

5 wks / abcnews

5 wks / abcnews


Surging outbreak: cases, deaths and WHO alarm

5 wks / abcnews

6 wks / abcnews


All Other Stories





Related Stories


Dual Lassa–rabies vaccine phase 1 shows safety in humans / 3 months

Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 4 months

Pfizer's Lyme vaccine heads to FDA after mixed trial results / 5 months

Experimental plague vaccine protects immune‑deficient mice from pneumonic plague / 6 wks

UK begins human testing of first AI-designed 'universal' vaccine / 3 months

Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months

Engineered 15‑strain biotherapeutic matches donor FMT for C. difficile / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Public Health, Eli Lilly, Diagnostics and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.